ZUMA-4 preliminary results: phase 1 study of KTE-C19 chimeric antigen receptor T cell therapy in pediatric and adolescent patients (pts) with relapsed/refractory acute lymphoblastic leukemia (R/R ALL)

被引：0
|
作者：
Lee, D. W. [1 ]
Wayne, A. S. [2 ]
Huynh, V. [3 ,4 ]
Handgretinger, R. [5 ]
Pieters, R. [6 ]
Michele, G. [7 ]
Baruchel, A. [8 ]
Feuchtinger, T. [9 ]
Bertrand, Y. [10 ]
Hemiston, M. [11 ]
Brown, P. A. [12 ]
Rossi, J. [13 ]
Jiang, Y. [14 ]
Navale, L. [14 ]
Stout, S. [15 ]
Aycock, J. [15 ]
Mardiros, A. [13 ]
Wiezorek, J. [15 ]
Jain, R. [15 ]
机构：
[1] Univ Virginia, Pediat Stem Cell Transplant Div Pediat Hematol On, Charlottesville, VA USA
[2] Univ Southern Calif, Keck Sch Med, USC Norris Comprehens Canc Ctr, Childrens Ctr Canc & Blood Dis,Childrens Hosp Los, Los Angeles, CA USA
[3] Childrens Hosp Orange Cty, Hyundai Canc Inst, Dept Epidemiol, Orange, CA 92668 USA
[4] Childrens Hosp Orange Cty, Hyundai Canc Inst, Chao Family Comprehens Canc Ctr, Orange, CA 92668 USA
[5] Eberhard Karls Univ Tubingen, Univ Childrens Hosp, Tubingen, Germany
[6] Princess Maxima Ctr Pediat Oncol, Pediat Oncol, Utrecht, Netherlands
[7] Marseille Univ, Ctr Hosp Univ, Hop la Timone, Marseille, France
[8] CHU Paris, Hop Robert Debre, Pediat Hematol, Paris, France
[9] Ludwig Maximilians Univ Munchen, Dr von Hauner Univ Childrens Hosp, Munich, Germany
[10] Ctr Hosp Univ, Dept Pediat Hematol & Immunol, Lyon, France
[11] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA
[12] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Sch Med, Pediat Leukemia Program, Baltimore, MD USA
[13] Kite Pharma, Translat Sci, Santa Monica, CA USA
[14] Kite Pharma, Biostat, Santa Monica, CA USA
[15] Kite Pharma, Clin Dev, Santa Monica, CA USA
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1008PD
引用
收藏
页数：2
相关论文
共 50 条
  • [1] KTE-C19 (anti-CD19 chimeric antigen receptor [CAR] T cell therapy) in pediatric and adolescent patients with relapsed/refractory acute lymphoblastic leukemia (R/R ALL): Preliminary Results of ZUMA-4
    Lee, Daniel W.
    Wayne, Alan
    Van Huynh
    Handgretinger, Rupert
    Pieters, Rob
    Michel, Gerard
    Baruchel, Andre
    Feuchtinger, Tobias
    Bertrand, Yves
    Hemiston, Michelle
    Brown, Patrick
    Rossi, John
    Jiang, Yizhou
    Navale, Lynn
    Stout, Shanna
    Aycock, Jeff
    Mardiros, Armen
    Wiezorek, Jeff
    Jain, Rajul
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 : S252 - S253
  • [2] UPDATED RESULTS FROM ZUMA-4: A PHASE 1/2 STUDY OF KTE-C19 CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL THERAPY IN PEDIATRIC AND ADOLESCENT PATIENTS WITH RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA
    Lee, D. W.
    Wayne, A. S.
    Huynh, V.
    Handgretinger, R.
    Brown, P. A.
    Pieters, R.
    Dietz, A. C.
    Pulsipher, M. A.
    Rossi, J.
    Mardiros, A.
    Jiang, Y.
    Navale, L.
    Aycock, J.
    Stout, S.
    Wiezorek, J.
    Jain, R.
    HAEMATOLOGICA, 2017, 102 : 346 - 347
  • [3] Phase 1 Results of ZUMA-3: KTE-C19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia (R/R ALL)
    Shah, Bijal D.
    Stock, Wendy
    Wierda, William G.
    Oluwole, Olalekan
    Holmes, Houston
    Schiller, Gary J.
    Topp, Max S.
    Kersten, Marie Jose
    Houot, Roch
    Boissel, Nicolas
    Mojadidi, Michelle
    Xue, Allen
    Mardiros, Armen
    Jiang, Yizhou
    Shen, Tong
    Aycock, Jeff S.
    Stout, Shanna
    Wiezorek, Jeffrey S.
    Jain, Rajul
    BLOOD, 2017, 130
  • [4] KTE-C19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T cell Therapy in Adult Patients (Pts) With Relapsed/Refractory Acute Lymphoblastic Leukemia (R/R ALL) in the ZUMA-3 Trial: Preliminary Results of Novel Safety Interventions
    Shah, Bijal
    Stock, Wendy
    Wierda, William
    Topp, Max
    Kersten, Marie Jose
    Houot, Roch
    Boissel, Nicolas
    Holmes, Houston
    Schiller, Gary
    Mardiros, Armen
    Rossi, John
    Jiang, Yizhou
    Shen, Tong
    Aycock, Jeff
    Stout, Shanna
    Wiezorek, Jeff
    Jain, Rajul
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 : S253 - S253
  • [5] Updated results from ZUMA-3, a phase 1/2 study of KTE-C19 chimeric antigen receptor (CAR) T cell therapy, in adults with high-burden relapsed/refractory acute lymphoblastic leukemia (R/R ALL).
    Shah, Bijal D.
    Wierda, William G.
    Schiller, Gary J.
    Bishop, Michael Russell
    Castro, Januario E.
    Sabatino, Marianna
    Bot, Adrian
    Mardiros, Armen
    Rossi, John
    Jiang, Yizhou
    Navale, Lynn
    Stout, Shanna
    Aycock, Jeff
    Wiezorek, Jeffrey S.
    Jain, Rajul K.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [6] KTE-C19 CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL THERAPY IN ADULTS WITH HIGH-BURDEN RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA (R/R ALL): UPDATED RESULTS FROM PHASE 1/2 OF ZUMA-3
    Shah, B.
    Wierda, W. G.
    Schiller, G. J.
    Bishop, M. R.
    Castro, J. E.
    Sabatino, M.
    Mardiros, A.
    Rossi, J.
    Jiang, Y.
    Navale, L.
    Stout, S.
    Aycock, J.
    Wiezorek, J.
    Jain, R.
    HAEMATOLOGICA, 2017, 102 : 200 - 200
  • [7] Outcomes of patients (pts) treated with prior blinatumomab (Blin) in ZUMA-3: A study of KTE-C19, an anti-CD19 chimeric antigen receptor (CAR) t cell therapy, in adult pts with relapsed/refractory acute lymphoblastic leukemia (R/R ALL).
    Shah, Bijal D.
    Oluwole, Olalekan O.
    Baer, Maria R.
    Bishop, Michael Russell
    Holmes, Houston Eccleston
    Schiller, Gary J.
    Donnellan, William Bruce
    Carr-O'Dwyer, Kristen Marie
    Mardiros, Armen
    Rossi, John M.
    Shen, Tong
    Xue, Allen
    Jain, Rajul K.
    Vezan, Remus
    Wierda, William G.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [8] Updated Phase 1 Results of Zuma-3: Kte-C19, an Anti-CD19 Chimeric Antigen Receptor T Cell Therapy, in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia
    Wierda, William G.
    Bishop, Michael R.
    Oluwole, Olalekan O.
    Logan, Aaron C.
    Baer, Maria R.
    Donnellan, William B.
    O'Dwyer, Kristen M.
    Castro, Januario E.
    Schiller, Gary J.
    Holmes, Houston
    Abedi, Mehrdad
    Ghobadi, Armin
    Arellano, Martha L.
    Malone, Adriana K.
    Pagel, John M.
    Mardiros, Armen
    Shen, Tong
    Vezan, Remus
    Jain, Rajul K.
    Shah, Bijal D.
    BLOOD, 2018, 132
  • [9] ZUMA-4: A phase 1/2 multicenter study evaluating the safety and efficacy of KTE-C19 (anti-CD19 CAR T cells) in pediatric and adolescent subjects with relapsed/refractory B-precursor acute lymphoblastic leukemia (r/r ALL).
    Wayne, Alan S.
    Sender, Leonard S.
    Lee, Daniel Warnell
    Handgretinger, Rupert
    Brown, Patrick A.
    Jiang, Yizhou
    Navale, Lynn
    Stout, Shanna
    Aycock, Jeff
    Wiezorek, Jeffrey S.
    Jain, Rajul K.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [10] ZUMA-4 Phase 1: KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Children and Adolescents with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL)
    Wayne, A. S.
    Huynh, V.
    Hijiya, N.
    Rouce, R.
    Brown, P. A.
    Krueger, J.
    Rytting, M.
    Kitko, C. L.
    Dela Ziga, E.
    Hermiston, M.
    Richards, M. K.
    Baruchel, A.
    Mardiros, A.
    Shen, T.
    Goyal, L.
    Vezan, R.
    Jain, R.
    Lee, D. W.
    PEDIATRIC BLOOD & CANCER, 2019, 66 : S7 - S7
12345